Vestal Point Capital LP Makes New Investment in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Vestal Point Capital LP acquired a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 250,000 shares of the biotechnology company’s stock, valued at approximately $30,398,000. Sarepta Therapeutics accounts for approximately 1.8% of Vestal Point Capital LP’s investment portfolio, making the stock its 24th biggest position. Vestal Point Capital LP owned approximately 0.26% of Sarepta Therapeutics at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Manchester Capital Management LLC boosted its holdings in Sarepta Therapeutics by 86.6% in the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 110 shares during the period. MassMutual Private Wealth & Trust FSB lifted its stake in Sarepta Therapeutics by 169.6% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 156 shares during the last quarter. Newbridge Financial Services Group Inc. bought a new stake in Sarepta Therapeutics in the fourth quarter valued at $36,000. Steward Partners Investment Advisory LLC lifted its stake in Sarepta Therapeutics by 164.4% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 194 shares during the last quarter. Finally, Smartleaf Asset Management LLC lifted its stake in Sarepta Therapeutics by 95.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company’s stock valued at $54,000 after buying an additional 216 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Scotiabank cut their target price on Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating on the stock in a research note on Thursday, March 20th. Evercore ISI cut Sarepta Therapeutics from an “outperform” rating to an “inline” rating and set a $50.00 target price on the stock. in a research note on Thursday, May 8th. UBS Group cut their target price on Sarepta Therapeutics from $188.00 to $85.00 and set a “buy” rating on the stock in a research note on Thursday, May 8th. HC Wainwright cut their target price on Sarepta Therapeutics from $75.00 to $40.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 7th. Finally, Oppenheimer cut their price objective on shares of Sarepta Therapeutics from $184.00 to $123.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 7th. Six analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $124.36.

Insider Activity at Sarepta Therapeutics

In related news, Director Claude Nicaise sold 2,491 shares of the business’s stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares of the company’s stock, valued at approximately $2,771,187.68. The trade was a 8.22% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 7.70% of the stock is currently owned by company insiders.

Sarepta Therapeutics Trading Up 3.3%

Shares of SRPT opened at $36.43 on Monday. The business’s 50-day moving average price is $60.11 and its 200 day moving average price is $97.18. The stock has a market capitalization of $3.58 billion, a P/E ratio of 29.14 and a beta of 0.85. Sarepta Therapeutics, Inc. has a 1-year low of $34.10 and a 1-year high of $173.25. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The business had revenue of $744.86 million for the quarter, compared to analysts’ expectations of $685.75 million. During the same period last year, the firm earned $0.73 EPS. The company’s revenue was up 80.2% compared to the same quarter last year. Analysts expect that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.